Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

302
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Hepatic Portal System01:21

Hepatic Portal System

6.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.9K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

268
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
268

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of arecoline-induced mouse model for oral submucous fibrosis: An in vitro and in vivo study.

Archives of oral biology·2026
Same author

Drug-Induced Liver Injury From a Novel Antifungal - Olorofim.

ACG case reports journal·2026
Same author

Three-dimensional modeling of sensory nerve architecture and eosinophil and mast cell interactions in eosinophilic gastrointestinal disease.

Journal of leukocyte biology·2026
Same author

Clinical features, genetics, treatment, and long-term outcomes of STAT3 hyper-IgE syndrome: Single-center cohort analysis.

The Journal of allergy and clinical immunology·2026
Same author

Exceptionally Long Recurrence-Free Survival in a Male Patient With Fibrolamellar Hepatocellular Carcinoma.

Case reports in hepatology·2026
Same author

RASP: rapid antibody functional screening by pentavalent phage display.

mAbs·2026

Related Experiment Video

Updated: Mar 3, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Hepatic Capillariasis- Drug Targets.

Abhishek Dubey1, Antara Bagchi2, Disha Sharma1

  • 1King Edward Memorial Hospital, Mumbai, Maharashtra, India.

Infectious Disorders Drug Targets
|May 3, 2017
PubMed
Summary

Hepatic capillariasis, a rare zoonotic infection from Capillaria hepatica, causes liver disease in humans. Early diagnosis and treatment are crucial for managing this parasitic infection.

Keywords:
Capillaria hepaticaanti-nematode drugsgranulomatous inflammationliver biopsyparasitic infestationrodents

More Related Videos

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.9K
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

586

Related Experiment Videos

Last Updated: Mar 3, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.9K
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

586

Area of Science:

  • Zoonotic diseases
  • Parasitology
  • Hepatology

Background:

  • Zoonotic infections pose significant public health risks, often linked to environmental factors.
  • Hepatic capillariasis, caused by Capillaria hepatica, is a rare zoonotic disease primarily affecting rodents but with hepatic manifestations in humans.

Purpose of the Study:

  • To highlight the clinical significance of hepatic capillariasis.
  • To emphasize the importance of considering this diagnosis in endemic areas.

Main Methods:

  • Review of clinical presentations, diagnostic methods, and treatment options for hepatic capillariasis.
  • Analysis of the parasite's life cycle and its impact on the human liver.

Main Results:

  • Infection occurs via embryonated Capillaria hepatica eggs, leading to liver colonization, inflammation, and fibrosis.
  • Clinical signs include fever, abdominal pain, hepatomegaly, and eosinophilia; spurious infections present with gastrointestinal symptoms.
  • Diagnosis involves imaging (ultrasonography, CT), biopsy, and serological tests (ELISA, IIFT).

Conclusions:

  • Hepatic capillariasis requires consideration in differential diagnoses for hepatitis, leptospirosis, and other liver/parasitic infections.
  • Prompt diagnosis and treatment with antiparasitic drugs (benzimidazoles) and corticosteroids are essential for patient outcomes.